Skip to Main Content

Author Details

Heiko Sch??der
Memorial Sloan Kettering Cancer Center
1991
291
72
PMIDPaper TitleJournal TitlePublished Year
37729552Beyond the <i>AJR</i>: Follow-Up Imaging With FDG PET/CT in Head and Neck Cancer Improves Patient Outcome.AJR Am J Roentgenol2024
37646672Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.Haematologica2024
37646671Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.Haematologica2024
35882728Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use.Mol Imaging Biol2023
37908719Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.Theranostics2023
37794809Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab.Leuk Lymphoma2023
37722357Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.Blood Adv2023
37247180Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT.J Neurooncol2023
37246997Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT).Eur J Nucl Med Mol Imaging2023
37307213Retrospective characterization of nodal marginal zone lymphoma.Blood Adv2023
37099979Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity.Oral Oncol2023
36858729Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.Lancet Oncol2023
36549918Prognostic Value of <sup>18</sup>F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen.J Nucl Med2023
36587744Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.Transplant Cell Ther2023
36713355Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.Hemasphere2023
36396457Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumors.J Nucl Med2023
36576355Brown adipose tissue is not associated with cachexia or increased mortality in a retrospective study of patients with cancer.Am J Physiol Endocrinol Metab2023
36604326PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.Eur J Nucl Med Mol Imaging2023
36604182Long-Term Prognostic Value of <sup>82</sup>Rb PET/CT-Determined Myocardial Perfusion and Flow Reserve in Cancer Patients.J Nucl Med2023
36799072Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis.Cancer Med2023
365994742022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2.J Nucl Med2023
36418168Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using <sup>89</sup>Zr-Trastuzumab PET: A Pilot Study.J Nucl Med2023
36484627Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.Br J Haematol2023
36269899Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).J Clin Oncol2023
36357178Detecting CXCR4 Expression in Meningioma on <sup>68</sup>Ga-Pentixafor PET/MRI.J Nucl Med2023
34772795The Quest for an Accurate Functional Tumor Volume with <sup>68</sup>Ga-DOTATATE PET/CT.J Nucl Med2022
35482115Correction to: Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.Eur J Nucl Med Mol Imaging2022
35609558Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE.Neuroendocrinology2022
35725926Radiotheranostics in oncology: current challenges and emerging opportunities.Nat Rev Clin Oncol2022
35523007Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management.Transl Oncol2022
364561122022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1.J Nucl Med2022
36180071Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.J Immunother Cancer2022
36334589Architecture of the outbred brown fat proteome defines regulators of metabolic physiology.Cell2022
36137649Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.J Immunother Cancer2022
36258098TriDFusion (3DF) image viewer.EJNMMI Phys2022
36115426Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation.Urology2022
35015566Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.J Clin Oncol2022
35066001Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG-PET/CT external beam radiation treatment planning in lung cancer.Radiother Oncol2022
35210300Impact of ComBat Harmonization on PET Radiomics-Based Tissue Classification: A Dual-Center PET/MRI and PET/CT Study.J Nucl Med2022
35145059Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.Blood Cancer J2022
35266033Correction to: [[89]Zr]Zrâ¿¿huJ591 immunoâ¿¿PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.Eur J Nucl Med Mol Imaging2022
34992152The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup>F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma.J Nucl Med2022
35022844Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.Eur J Nucl Med Mol Imaging2022
34498111[[89]Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.Eur J Nucl Med Mol Imaging2022
34615723Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.Clin Cancer Res2022
34773473Comparing the clinical performance and cost efficacy of [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis.Eur J Nucl Med Mol Imaging2022
32959115Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE.Eur J Nucl Med Mol Imaging2021
33494586Interventional molecular imaging.Q J Nucl Med Mol Imaging2021
33494585Practice and prospects for PET/CT guided interventions.Q J Nucl Med Mol Imaging2021
33909449Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.J Clin Oncol2021
  • 1 - 50 of 291

Recommended Authors

University of Wisconsin-Madison
Career Start Year 2013
Number of shared co-authors 7
Lausanne University Hospital and University of Lausanne
Career Start Year 2011
Number of shared co-authors 0
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2010
Number of shared co-authors 11
Princess Margaret Cancer Centre
Career Start Year 2010
Number of shared co-authors 3
The First Hospital of Shanxi Medical University
Career Start Year 2009
Number of shared co-authors 0
Massachusetts General Hospital
Career Start Year 2008
Number of shared co-authors 1
University of California san francisco
Career Start Year 2007
Number of shared co-authors 8
Clinical Center
Career Start Year 2006
Number of shared co-authors 6
The Institute of Cancer Research
Career Start Year 2005
Number of shared co-authors 10
National Institute of Mental Health & Neurosciences (NIMHANS)
Career Start Year 2005
Number of shared co-authors 1
Stanford University
Career Start Year 2005
Number of shared co-authors 0
University of California san francisco
Career Start Year 2005
Number of shared co-authors 6
Memorial Sloan Kettering Cancer Center.
Career Start Year 2002
Number of shared co-authors 20
Peking University
Career Start Year 2002
Number of shared co-authors 0
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Career Start Year 2000
Number of shared co-authors 0
Nepean Hospital
Career Start Year 1999
Number of shared co-authors 0
Harvard Medical School
Career Start Year 1999
Number of shared co-authors 14
University of Wisconsin Hospitals and Clinics
Career Start Year 1998
Number of shared co-authors 0
Singapore General Hospital
Career Start Year 1997
Number of shared co-authors 0
Radboud University, Nijmegen Medical Centre
Career Start Year 1995
Number of shared co-authors 13
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 1
First Medical Center, Chinese PLA General Hospital
Career Start Year 1994
Number of shared co-authors 0
Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO
Career Start Year 1993
Number of shared co-authors 8
Clinical Center, National Institutes of Health
Career Start Year 1989
Number of shared co-authors 4
David Geffen School of Medicine, university of california los angeles
Career Start Year 1988
Number of shared co-authors 10
University of California san francisco
Career Start Year 1986
Number of shared co-authors 5
Massachusetts General Hospital
Career Start Year 1984
Number of shared co-authors 0
National Cancer Institute, National Institutes of Health
Career Start Year 1982
Number of shared co-authors 8
First Medical Center of Chinese PLA General Hospital
Career Start Year 1982
Number of shared co-authors 0
Keck School of Medicine of USC
Career Start Year 1971
Number of shared co-authors 1

Collaborators

Memorial Sloan Kettering Cancer Center
Co-authored papers 43
Co-authored papers 31
Memorial Sloan Kettering Cancer Center
Co-authored papers 28
Memorial Sloan Kettering Cancer Center
Co-authored papers 14
university of california los angeles
Co-authored papers 12
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Memorial Sloan-Kettering Cancer Center
Co-authored papers 9
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
David Geffen School of Medicine at university of california los angeles
Co-authored papers 6
University of California san francisco
Co-authored papers 6
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Rutgers Robert Wood Johnson Medical School
Co-authored papers 4
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Weill Cornell University
Co-authored papers 3
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Department of Radiology Memorial Sloan Kettering Cancer Center
Co-authored papers 3
University of California los angeles
Co-authored papers 3
German Cancer Research Center (DKFZ)
Co-authored papers 3
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Co-authored papers 3